Technology

Cytox's technology is based on discoveries made by the company's scientific founder, Dr. Zsuzsanna Nagy, of cell cycle-related biomarkers associated with the risk of developing Alzheimer’s disease (AD). The cell cycle hypothesis postulates that dysfunction of the G1/S regulatory mechanism allows brain neurons to (abnormally) progress to the late stages of the cell cycle, where they produce plaques and tangles, the hallmark pathologies of AD.

Cytox has developed technologies and products based on the role of the cell cycle in AD, including a lymphocyte-based test to predict conversion from mild cognitive impairment to AD; genomic tests to predict individual patients' responses to treatment; and a medium throughput, high content drug screen for the discovery of disease-modifying therapeutics.